DALLAS, March 12, 2010 (GLOBE NEWSWIRE) -- BeaconEquity.com announces an investment report featuring biotechnology company BioSante Pharmaceuticals Inc. (Nasdaq:BPAX). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.
The full report is available at: http://www.beaconequity.com/i/BPAX
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity
BioSante Pharmaceuticals Inc. (BPAX) is a specialty pharmaceutical company focused on developing products for female sexual health, menopause, contraception and male hypogonadism. The Company primary products include gel formulations of testosterone and estradiol. It is also engaged in the development of its calcium phosphate nanotechnology (CaP), primarily for aesthetic medicine, vaccines and drug delivery.
Message Board Search: http://www.boardcentral.com/boards/BPAX
In the report, the analyst notes:
"BPAX incurred a net loss of approximately $6.4 million or ($0.21) per share for the quarter ended September 30, 2009, compared to a net loss of $6.6 million or ($0.24) per share for the same period in 2008. This decrease in net loss was due to BPAX's decision in April 2009 to delay screening of new subjects for its ongoing LibiGel® (testosterone gel) phase III safety study, partially offset by the recognition of acquisition related costs of approximately $1.5 million related to the Company's merger with Cell Genesys Inc., which closed October 14, 2009. Screening of new subjects for the safety study has been reinitiated.
"BPAX yesterday announced that studies of its GVAX vaccine showed the vaccine to be effective in battling chronic myeloid leukemia (CML). The vaccine was tested on patients with CML who were not responding as hoped to the leading treatment Gleevec. The study was conducted at Johns Hopkins Kimmel Cancer Center in Baltimore, Maryland."
To read the entire report visit: http://www.beaconequity.com/i/BPAX
See what investors are saying about BPAX at penny stock forum
BeaconEquity.com is one of the industry's largest small-cap report providers. Beacon strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, please visit http://www.BeaconEquity.com
Beacon Equity Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. Beacon Equity Research nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.